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Purine and pyrimidine metabolism was compared in erythrocytes from three 
patients from two families with purine nucleoside phosphorylase deficiency and 
T-cell immunodeficiency, one heterozygote subject for this enzyme deficiency, 
one patient with a complete deficiency of hypoxanthine-guanine phosphoribosyl- 
transferase, and two normal subjects. The erythrocytes from the heterozygote 
subject were indistinguishable from the normal erythrocytes. The purine nucleo- 
side phosphorylase deficient erythrocytes had a block in the conversion of inosine 
to hypoxanthine. The erythrocytes with 0.07%o of normal purine nueleoside 
phosphorylase activity resembled erythrocytes with hypoxanthine-guanine phos- 
phoribosyltransferase deficiency by having an elevated intracellular concentra- 
tion of PP-ribose-P, increased synthesis of PP-ribose-P, and an elevated rate of 
carbon dioxide release from orotic acid during its conversion to UMP. Two 
hypotheses to account for the associated immunodeficiency--that the enzyme 
deficiency leads to a block of PP-ribose-P synthesis or inhibition of pyrimidine 
synthesis--could not be supported by observations in erythrocytes from both 
enzyme-deficient families. 
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INTRODUCTION 
A multiplicity of phenotypic expression is associated with inborn errors of 
purine metabolism. Profound central nervous system dysfunction, hyperuri- 
cemia, renal calculi, and gout accompany the complete deficiency ofhypoxan- 
thine-guanine phosphoribosyltransferase (Lesch and Nyhan, 1964; Kelley et 
al., 1967; Rosenbloom et al., 1967; Kelley and Wyngaarden, 1972). Disorders 
of immune function are associated with a deficiency of adenosine deaminase 
(Giblett et al., 1972; Meuwissen et al., 1975) or purine nucleoside phosphory- 
lase (Giblett et al., 1975; Cohen et al., 1976; Hamet et al., 1977; Siegenbeek van 
Heukel0m et al., 1977; Stoop et al., 1977; Edwards et al., 1978; Gelfand et al., 
1978a; Rich et al., 1979). 
The absence of purine nucleoside phosphorylase causes biochemical 
features similar to the deficiency of hypoxanthine-guanine phosphoribosyl- 
transferase. Both enzyme deficiencies are associated with purine overproduc- 
tion (Lesch and Nyhan, 1964; Kelley et al., 1967; Rosenbloorn et al., 1967; 
Kelley and Wyngaarden, 1972; Cohen et al., 1976; Siegenbeek van Heukelom 
et al., 1977; Edwards et al., 1978) and both are characterized by elevated 
concentrations of erythrocyte PP-ribose-P (Fox and Kelley, 1971b; Cohen et 
al., 1976; Siegenbeek van Heukelom et al., 1977). These similar features may 
result from the two enzymes occurring in series in the purine catabolic 
pathway (Fig. 1). 
Our recent studies of fresh erythrocytes from two families with purine 
necleoside phosphorylase deficiency and one patient with complete hypoxan- 
thine-guanine phosphoribosyltransferase deficiency have afforded the oppor- 
tunity to compare the biochemical changes of these two enzyme deficiencies. 
We have asked specific questions with reference to purine nucleoside phos- 
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Fig. 1. Relationship of purine nucleoside 
phosphorylase and hypoxanthine-guanine 
phosphoribosyltransferase in human eryth- 
rocytes. Purine nucleoside phosphorylase 
(reaction 2) and hypoxanthine-guanine 
phosphoribosyltransferase (reaction 3) 
represent sequential steps of nucleoside 
metabolism in human erythrocytes. The pro- 
ducts of reaction 2 are the substrates for 
reaction 3. Adenosine may be either dea- 
minated to inosine by adenosine deaminase 
(reaction 1) or phosphorylated to AMP by 
adenosine kinase (reaction 4). Deoxyadeno- 
sine, deoxyinosine, and deoxyguanosine are 
degraded to hypoxanthine and guanine by 
the same reactions as their ribonucleoside 
derivatives (Fox, 1978; Fox and Kelley, 
1978). 
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phorylase deficiency: (1) Is disordered erythrocyte metabolism similar in 
purine nucleoside phosphorylase and hypoxanthine-guanine phosphoribosyl- 
transferase deficiencies? (2) Is there evidence for biochemical abnormalities in 
erythrocytes from a heterozygote for purine nucleoside phosphorylase defi- 
ciency? (3) Is there evidence for decreased PP-ribose-P synthesis and inhibi- 
tion of pyrimidine synthesis as potential mechanisms for immunodeficiency in 
purine nucleoside phosphorylase deficiency? We have studied normal and 
enzyme-deficient erythrocytes to answer these questions. 
MATERIALS AND METHODS 
Adenosine, tetrasodium PP-ribose-P, inosine, IMP, ADP, ATP, deoxyadeno- 
sine, deoxyinosine, and deoxyguanosine were purchased fromSigma Chemi- 
cal Company (St. Louis, Missouri). Adenine and hypoxanthine were pur- 
chased from Calbiochem (San Diego, California). EHNA, inhibitor of adeno- 
sine deaminase, was a gift from Dr. Gertrude Elion of Burroughs Wellcome 
Company (Research Triangle Park, North Carolina). From Amersham Cor- 
poration (Chicago, Illinois) we purchased [8-14C]inosine (60 mCi/mM) and 
[U-14C] adenine (270 mCi/mM). From New England Nuclear Corporation 
(Boston, Massashusetts), we purchased [8-14C] adenosine (54.7 mCi/mM), 
[8-14C] adenine (52 mCi/mM), and [carboxyl-14C]orotic acid (41:25 mCi/mM). 
Two brothers, ages 9 and 10 years (family 1), with purine nucleoside 
phosphorylase deficiency were hospitalized at the Hospital for Sick Children 
in Toronto. One child, age 5, with purine nucleoside phosphorylase deficiency 
(family 2) was hospitalized at the Children's Hospital in Chicago. The clinical 
features of these patients are described elsewhere (Edwards et al., 1978; 
Gelfand et al., 1978a; Rich et al., 1979). Erythrocytes for in vitro studies of 
purine metabolism or enzyme assay were obtained by collecting fresh blood 
into heparin treated tubes at 4 C from three patients with purine nucleoside 
phosphorylase deficiency (families 1 and 2), one patient with a deficiency of 
hypoxanthine-guanine phosphoribosyltransferase, one heterozygote for 
purine nucleoside phosphorylase deficiency (family 2), and two normal sub- 
jects. Erythrocytes were spun at 1000g at 4 C for 5 rain, and plasma was 
removed and frozen at - 20 C. Erythrocytes were washed twice with cold 150 
m~ sodium chloride and were used immediately for in vitro studies or frozen at 
- 70 C for enzyme assay. 
In vitro studies ofpurine nucleoside phosphorylase-deficient erythrocytes 
were compared with normal and hypoxanthine-guanine phosphoribosyl- 
transferase deficient erythrocytes. Erythrocytes were incubated in a 100/A 
medium containing 2.5-20 #1 erythrocytes, 7 mM glucose, 150 mM sodium 
chloride, 67 m~ tris-HC1 (pH 7.4), 4-6 m~ disodium phosphate, and 0-1.25 
m~ nucleoside. The metabolism of 37 ktM [8-14C] adenosine or 41 pM [8-14C] 
224 Fox, Kaminska, Edwards, Gelfand, Rich, and Arnold 
inosine was studied by incubating the reaction mixture for 5-10 rain according 
to methods previously described (Planet and Fox, 1976; Edwards et  al., 1978). 
Available PP-ribose-P was measured by adding 20 gM [8-14C] adenine to the 
incubation medium (Henderson and Khoo, 1965; Planet and Fox, 1976; 
Edwards et  al., 1978). Free PP-ribose-P was assayed with a radiochemical 
method using [U-14C] adenine (Fox and Kelley, 197 la). The rate of conversion 
of orotic acid to UMP in erythrocytes was quantitated by the release of 14CO2 
from [carboxyl-14C]orotic acid (Edwards et  al. ,  1978; Fox et al., 1978). Inor- 
ganic phosphate was quantitated according to the method of Chen et  al. 
(1956). Hypoxanthine-guanine and adenine phosphoribosyltransferases, PP- 
ribose-P synthetase, adenosine deaminase, and purine nucleoside phosphory- 
lase were assayed by previously described radiochemical methods (Kelley et  
al., 1967; Fox and Kelley, 1971a; Van der Weyden et  al., 1974; Fox et  al., 
1977). Protein was estimated by the method of Lowry et  al. (1951) using 
crystalline bovine serum albumin as a standard. The concentrations of com- 
pounds used in these studies were based on the description provided by the 
manufacturer. Erythrocytes from each faimily were studied separately with a 
normal control for comparison. 
RESULTS 
Erythroeyte Enzyme Levels 
Purine nucleoside phosphorylase was severely deficient with a value of 0.07% 
of control activity in the affected child from family 2, while the two brothers 
from family 1 were partially deficient with 0.45% of normal erythrocyte purine 
nucleoside phosphorylase activity. The mother of the enzyme-deficient child 
from family 2 had purine nucleoside phosphorylase activity which was 45% of 
normal. Normal erythrocyte purine nucleoside phosphorylase has a value of 
2166+_576 nmol/hr/mg (Fox et  al., 1977). The patient with Lesch-Nyhan 
syndrome had a complete deficiency of erythrocyte hypoxanthine-guanine 
phosphoribosyltransferase and normal purine nucleoside phosphorylase. 
Block at Purine Nucleoside Phosphorylase 
Since the affected patients from both families had a measurable amount of 
purine nucleoside phosphorylase, the degree of block at purine nucleoside 
phosphorylase was estimated in intact cells by examining the conversion of 
inosine to hypoxanthine and the decrease of inorganic phosphate concentra- 
tions following the addition of inosine. Inosine and inorganic phosphate are 
substrates for purine nucleoside phosphorylase. Fresh erythrocytes were incu- 
bated with [8J4C] inosine, and the formation of [14C]hypoxanthine was quan- 
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titated (Table I). Normal erythrocytes converted 9-21~ o of inosine to hypo- 
xanthine at 6.5 mM inorganic phosphate. The erythrocytes from the affected 
child in family 2 did not convert any inosine to hypoxanthine, indicating a 
virtually complete block at purine nucleoside phosphorylase. The erythro- 
cytes from the two affected brothers from family 1 converted a small but 
substantial amount of inosine to hypoxanthine, indicating an incomplete 
block of purine nucleoside phosphorylase in the intact erythrocytes. 
When inosine is converted to hypoxanthine, inorganic phosphate is 
utilized as a substrate to form ribose-l-phosphate. Patients with purine 
nucleoside phosphorylase deficiency demonstrate resistance to the inosine- 
induced decreased in inorganic phophate (Table I), indicating decreased 
utilization of inorganic phosphate to form ribose-l-phosphate. 
Erythrocytes from the heterozygote of family 2 and the patient with 
Lesch-Nyhan syndrome were indistinguishable from normal erythrocytes in 
their capacity to form hypoxanthine from inosine or to utilize inorganic 
phosphate. 
Biochemical Effects of the Enzyme Deficiency 
Inhibition of PP-ribose-P formation and blockade of pyrimidine biosynthesis 
are two mechanisms suggested as potential bases for immunodeficiency in the 
purine enzyme deficiency states (Green and Chan, 1973; Ishii and Green, 
1973; Planet and Fox, 1976; Snyder et al., 1976; Fox et al., 1978). These 
Table I. Block at Purine Nucleoside Phosphorylase a 
Hypoxanthine formation b 
(% [8-14C] inosine utilized) 
Phosphate concentration c 
(% control value with 
inosine 1.25 raM) 
Family 1 
Normal 9 42 
P N P -  (A) 0.5 92 
P N P -  (B) 0.8 91 
Lesch-Nyhan syndrome 9 46 
Family 2 
Normal 21 49 
P N P -  Not detectable 82 
Heterozygote 24 41 
a P N P - ,  Purine nucleoside phosphorylase deficiency; heterozygote, heterozygote 
for purine nucleoside phosphorylase deficiency. 
Calculated for 2.5/A erythrocytes incubated for 6 rain. 
e Concentration estimated following a 30-rain incubation with 1.25 mM inosine. 
Control values ranged from 0.78 to 0.91 mM for study 1 and 1.55 to 1.95 mM for 
study 2. 
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hypotheses were testable in erythrocytes because they have the pathway for 
PP-ribose-P synthesis and the pathway for the formation of pyrimidine 
nucleotides from orotic acid. PP-ribose-P concentration in the erythrocytes 
from the affected child of family 2 was increased by 284% above the control 
value, while the PP-ribose-P concentration from the erythrocytes from the 
brothers from family 1 were increased slightly by 22% or 120%. The erythro- 
cyte PP-ribose-P concentration in the heterozygote (family 2) was not in- 
creased, while the erythrocyte PP-ribose-P concentration in the Lesch-Nyhan 
patient was 2345% above the control value. Thus there was a modest increase 
in PP-ribose-P concentrations in erythrocytes in the patient from family 2. 
The possibility that an accumulation of nucleosides in purine nucleoside 
phosphorylase deficiency might alter PP-ribose-P formation was further 
tested. The basis for this hypothesis is the ability of nucleosides to reduce 
intracellular concentrations of PP-ribose-P in human erythrocytes, human 
lymphoblasts, and Escheriehia coli (Bagnara and Finch, 1973, 1974; Planet 
and Fox, 1976; Snyder et al., 1976; Snyder and Seegmiller, 1976). Since 
PP-ribose-P is an essential substrate for pyrimidine biosynthesis de novo, 
purine biosynthesis de novo, and purine salvage pathways (Fox and Kelley, 
1971b), decreased intracellular concentration of this compound could have 
profound metabolic effects. An estimation of the capacity to synthesize 
PP-ribose-P was assessed by the measurement of 'available PP-ribose-P.' 
Purine nucleoside phosphorylase deficient erythrocytes did not have a de- 
crease of PP-ribose-P synthesis as measured under these conditions (Fig. 2). In 
erythrocytes from the affected brothers of family 1 there was a modest increase 
in baseline synthesis of PP-ribose-P, whereas the severely deficient erythro- 
cytes from the affected child from family 2 synthesized large quantities of 
PP-ribose-P similar to the level seen in the cells from the patient with Lesch- 
Nyhan syndrome. Erythrocytes from the heterozygote subject from family 2 
synthesized normal quantities of PP-ribose-P. 
Adenosine or inosine 1.25 mM markedly inhibited PP-ribose-P synthesis 
by normal erythrocytes and erythrocytes from the heterozygote subject (Fig. 
2). This reduction of intracellular concentrations of PP-ribose-P is caused by 
decreased synthesis of this compound as a result of the diminution of inor- 
ganic phosphate concentration by added nucleosides. In purine nucleoside 
phosphorylase deficiency the addition of inosine did not diminish PP-ribose-P 
levels and a decreased effect was evident with adenosine. This may be related 
to an inability to degrade inosine to hypoxanthine and the absence of a 
decrease in inorganic phosphate concentration (Planet and Fox, 1976). 
Another hypothesis is that a block of pyrimidine nucleotide synthesis 
could result from the purine nucleoside accumulation found in purine nucleo- 
side phosphorylase deficiency. The addition of adenosine to mammalian cells 
leads to (1) an accumulation of orotic acid, (2) a depletion of the pyrimidine 
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Fig. 2. PP-ribose-P synthesis in normal and enzyme-deficient 
erythrocytes. Fresh erythrocytes were obtained from normal sub- 
jects, patients with purine nucleoside phosphorylase deficiency 
(PNP-),  a patient with hypoxanthine-guanine phosphoribosyl- 
transferase deficiency ( H G P R T ) ,  and a heterozygote for purine 
nucleoside phosphorylase deficiency. Study 1 refers to experiments 
using erythrocytes from family 1 with 0.45~ of normal purine 
nucleoside phosphorylase in the affected brothers, and study 2 
refers to experiments on erythroeytes from family 2 with 0.07% of 
normal enzyme activity in the affected child. Enzyme-deficient 
erythrocytes are resistant to the inhibitory effects of added inosine 
and adenosine. 
nucleotide pool, and (3) an expansion of the adenine nucleotide pool (Kaukel 
et al., 1972; Green and Chan, 1973; Hilz and Kaukel, 1973; Ishii and Green, 
1973; Snyder and Seegmiller, 1976). These observations imply that adenosine 
inhibits pyrimidine biosynthesis at a site between orotic acid and UMP 
synthesis. Recently a block of pyrimidine synthesis in purine nucleoside 
phosphorylase deficiency was suggested by a minute elevation of urinary 
orotic acid in two patients with a complete enzyme deficiency (Cohen et al., 
1977). Baseline measurements in our studies did not demonstrate a block in 
UMP synthesis in the erythrocytes with purine nucleoside phosphorylase 
deficiency (Fig. 3). In fact, the erythrocytes from the affected child of family 2 
and from a patient with Lesch-Nyhan syndrome demonstrated a three- and 
five fold increase, respectively, in the baseline carbon dioxide release from 
orotic acid during its concersion to UMP. An increase in activity of orotate 
phosphoribosyltransferase and orotidylic decarboxylase occurs in erythro- 
cytes from patients with Lesch-Nyhan syndrome (Beardmore et al., 1973). 
Purine nucleoside phosphorylase deficient erythrocytes demonstrated a 
relative resistance to the inhibitory effects of inosine and to a smaller extent 
adenosine on carbon dioxide release from orotic acid (Fig. 3). The block in the 
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Fig. 3. Conversion of  orotic acid to UMP in normal and enzyme- 
deficient erythrocytes. Studies were carried out as described in Fig. 
2. The conversion of orotic acid to UMP was quantitated by the 
release of  14CO2 from [carboxyl-14C] orotic acid. 
release of carbon dioxide from orotic acid resulted from a depletion of 
intracellular PP-ribose-P, a substrate for orotate phosphoribosyltransferase 
reaction (Fox et  al., 1978). The inhibitory effect of purine nucleosides on this 
pyrimidine pathway in normal erythrocytes and the relative resistance to this 
effect in hypoxanthine-guanine phosphoribosyltransferase deficient cells 
agree with reported observations (Fox et  al., 1978). 
Effects of Deoxynucleosides 
It has recently become evident that nucleotide derivatives of 2'-deoxynucleo- 
sides accumulate in adenosine deaminase deficiency and purine nucleoside 
phosphorylase deficiency (Cohen et  al., 1978a,b; Coleman et  al., 1978). These 
are believed to result from the increase of deoxyadenosine levels in adenosine 
deaminase deficiency and deoxyguanosine levels in purine nucleoside phos- 
phorylase deficiency. Since a block of pyrimidine synthesis has been a promi- 
nent hypothesis used to explain immunodeficiency, it is of interest to consider 
whether these deoxynucleosides modify PP-ribose-P synthesis or the conver- 
sion of orotic acid to UMP. Using 2'-deoxynucleosides, there was a relative 
resistance to inhibition of PP-ribose-P synthesis and orotic acid conversion of 
UMP in purine nucleoside phosphorylase deficient erythrocytes with a severe 
enzyme deficiency (Table II). 
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Table II. Effect of Deoxynucleosides on PP-Ribose-P Synthesis and the 
Conversion of Orotic Acid to UMP in Erythrocytes (Studies on Blood 
from Individuals from Family 2) a 
229 
Percent of value with no inhibitor 
Inhibitor Heterozygote 
(1.25 raM) Normal PNP- for PNP- 
PP-ribose-P 
synthesis b 
dAdenosine 34 60 25 
dInosine 49 71 35 
dGuanosine 51 75 39 
Orotic acid conversion 
to UMP c 
dAdenosine 8 66 7 
dInosine 46 65 33 
dGuanosine 37 62 37 
a PNP- refers to purine nucleoside phosphorylase deficiency with 0.07~ 
normal activity. 
b See Fig. 2 for baseline values. 
~ See Fig. 3 for baseline values. 
D I S C U S S I O N  
Purine nucleoside phosphorylase catalyzes the reversible phosphorolysis of  
guanosine, deoxyguanosine, inosine, or deoxyinosine to guanine or hypoxan- 
thine. This reaction is of  critical importance to purine degradation and has 
been detected in extracts from human erythrocytes, lung, liver, spleen, kidney, 
muscle, and fibroblasts (Edwards et  al., 1971; Wor tmann et  al., 1979). This 
enzyme reaction precedes hypoxanthine-guanine phosphoribosyltransferase 
in the purine degradation pathway (Fig. 1). Hypoxanthine-guanine phos- 
phoribosyltransferase catalyzes the transfer of  the 5-phosphoribosyl moiety 
of  PP-ribose-P to the 9 position of  guanine, hypoxanthine, or xanthine to form 
GMP,  IMP, or XMP, respectively. The enzyme is present in many tissues in 
man, with the highest specific activities in brain, placenta, gonads, erythro- 
cytes, fibroblasts, and leukocytes (Rosenbloom et  al., 1967). The physiologi- 
cal role of  the enzyme may be related to a salvage function, allowing the 
conservation of purine bases that would otherwise be further degraded to uric 
acid (Henderson, 1968). 
The metabolic abnormalities of  purine nucleoside phosphorylase defi- 
ciency resemble to a great extent the disorders seen in the deficiency of  
hypoxanthine-guanine phosphoribosyltransferase. Previous studies have 
demonstrated urinary purine overexcretion to a level resembling that seen in 
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patients with Lesch-Nyhan syndrome (Lesch and Nyhan, 1964; Kelley et al., 
1967; Rosenbloom et al., 1967; Kelley and Wyngaarden, 1972; Cohen et al., 
1976; Siegenbeek van Heukelom et al., 1977; Edwards et al., 1978). As well, 
elevated erythrocyte PP-ribose-P concentrations have been described (Fox 
and Kelley, 1971b; Cohen et al., 1976; Siegenbeek van Heukelom et al., 1977). 
Our current studies of two families with purine nucleoside phosphorylase 
deficiency demonstrate that the erythrocytes from the patient with the more 
severe abnormality (family 2) resemble the erythrocytes from a patient with 
Lesch-Nyhan syndrome. Erythrocyte PP-ribose-P concentrations were ele- 
vated. The ability to synthesize PP-ribose-P by these erythrocytes and the 
production of carbon dioxide from orotic acid were also increased. 
The biochemical basis for the metabolic similarities of these two enzyme 
deficiencies is related to the fact that the deficiency of purine nucleoside 
phosphorylase leads to a secondary relative deficiency of hypoxanthine- 
guanine phosphoribosyltransferase. With the lack ofpurine nucleoside phos- 
phorylase activity, there is no production of hypoxanthine and guanine, 
substrates necessary for the hypoxanthine-guanine phosphoribosyltransfer- 
ase reaction. With the lack of substrate for the reaction, hypoxanthine- 
guanine phosphoribosyltransferase is no longer active and is relatively defi- 
cient despite the fact that the enzyme specific activity is normal. 
Despite these similarities in the biochemical alterations in deficiencies of 
purine nucleoside phosphorylase and hypoxanthine-guanine phosphoribosyl- 
transferase, there remain marked contrasts between these disorders. Although 
there is purine overproduction in both disorders, the net result is profoundly 
different. In hypoxanthine-guanine phosphoribosyltransferase deficiency 
there is accelerated oxidation of hypoxanthine to uric acid, as a result of an 
inability to reutilize this compound (Lesch and Nyhan, 1964; Kelley et al., 
1967; Rosenbloom et al., 1967; Kelley and Wyngaarden, 1972; Edwards et al., 
1979). Uric acid is inert metabolically. Our current observations and previous 
data (Cohen et al., 1976; Stoop et al., 1977; Edwards et al., 1978) indicate a 
block in the converson of nucleosides to uric acid in purine nucleoside 
phosphorylase deficiency. The net result is an accumulation of nucleosides 
and hypouricemia. Although inosine and guanosine appear not to be metabo- 
lized further when purine nucleoside phosphorylase is deficient, this is not the 
case with the 2'-deoxy derivatives of these compounds. Markedly increased 
concentrations of dGTP occur in erythrocytes from two previous patients 
with purine nucleoside phosphorylase deficiency (Cohen et al., 1978a) and the 
patients currently reported (Wortmann et al., 1979). It is believed that dGTP 
may be synthesized from accumulating deoxyguanosine and that this may be 
relevant to the observed disorder of cellular immunity. Accumulation of 
abnormal concentrations of intracellular nucleotides (Rosenbloom et aI., 
1968; Brenton et al., 1977; Nuki et al., 1977) or altered immune function 
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(Seegmiller et al., 1977; Gelfand et al., 1978) does not occur in the complete 
deficiency of hypoxanthine-guanine phosphoribosyltransferase. 
The erythrocytes from a subject with 45% of normal purine nucleoside 
phosphorylase activity (family 2) show no evidence of any alteration of 
metabolism. Previous studies had revealed a normal subject (Rich et al., 1979). 
This contrasts with patients with this degree of enzyme deficiency in hypoxan- 
thine-guanine phosphoribosyltransferase, who have evidence of uric acid 
overproduction (Fox, 1977). 
There are a number of hypotheses which have been proposed to account 
for the immunodeficiency in purine enzyme deficiency states (Fox and Kelley, 
1978; Fox, 1979). Inhibition of PP-ribose-P formation and a blockade of 
pyrimidine biosynthesis had appeared to provide an important molecular 
basis this association (Green and Chan, 1973; Ishii and Green, 1973; Planet 
and Fox, 1976; Snyder et al., 1976; Fox et al., 1978). The occurrence oforotic 
aciduria in two patients with purine nucleoside phosphorylase deficiency 
(Cohen et al., 1977) supported this mechanism. However, there is no evidence 
for inhibition of PP-ribose-P formation or block of pyrimidine synthesis in 
purine nucleoside phosphorylase deficient erythrocytes in the current study or 
in enzyme-deficient cultured human fibroblasts (Fox, 1978). The observations 
suggest that other mechanisms may be more important. A block at ribonu- 
cleotide reductase, an accumulation of S-adenosylhomocysteine, or elevated 
concentrations of cyclic-3',5'-AMP appear to be more viable mechanisms to 
explain the biochemical basis of immune dysfunction (Fox, 1979). 
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